Planning the Treatment Series With KYBELLA®

Help your patients draw a different line

kybella®

(deoxycholic acid) injection 10 mg/mL

NIKKI, AGE: 35

BEFORE



AFTER 4 TREATMENTS

JASON, AGE: 36



BEFORE



AFTER 6 TREATMENTS

Unretouched photos of paid models. Individual results may vary.
Not all treatments are shown; 59% of adults received 6 KYBELLA® treatments in clinical studies.[1]

Improve their chin profile by permanently destroying fat cells in the submental treatment area—1 treatment at a time[1]

INDICATION

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Please see Important Safety Information inside and accompanying full Prescribing Information.

ACT on the Opportunity

ASSESS: Determine Appropriate Candidates



- **Proactively start** the submental fullness conversation with patients as part of their full-face assessment
- **Use** the *ART* of Assessment®: *A*nimate, *R*otate, *T*ilt
- **Capture** profile photos and use them to educate patients about their submental profile
  – Use the **sloped chin line** as an easy, eye-catching, and relatable way to help patients visualize their chin profile

CONSULT: Manage Patient Expectations

- **Emphasize the need for a series of treatments** to see progressive results[1]
- **Ensure** patients are aware of possible treatment side effects, including swelling as an expected reaction to treatment[1]
  – *TIP:* Use the 1-day posttreatment swelling photos on the back cover to show patients examples of swelling
- **Consider** *treatment package pricing* to encourage patients to commit to their recommended treatment series

TREAT: Use Proper Injection Technique for Desired Aesthetic Outcomes

- **Address** all key submental fat areas within the approved Treatment Zone[1]
- **Administer** 0.2 mL per injection site,* following the established dosing standard[1]
- **Individually tailor**† treatment to each patient, based on severity, distribution of fat in the submental region, and aesthetic goals[1]

The first of its kind

- ✔ An injectable, nonsurgical option[1]
- ✔ Permanently destroys fat cells in the submental treatment area[1]
- ✔ Individually tailored† for an improved chin profile[1]

*No more than 10 mL, or 5 vials, of KYBELLA® may be administered per treatment session.[1]

†Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart.[1]

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Please see additional Important Safety Information on following pages.

kybella®
(deoxycholic acid) injection 10 mg/mL

DISCUSS THE SAFETY PROFILE

In addition to informing patients of product contraindications and warnings and precautions, remind patients about the potential for treatment-area adverse reactions[1]

- Edema/swelling
- Erythema
- Pain
- Numbness
- Induration

MANAGE PATIENT EXPECTATIONS OF SWELLING

Show these photos to help prepare patients that swelling is an expected reaction to treatment[1]



BEFORE | DAY 1 AFTER TREATMENT 1 | BEFORE TREATMENT 2

BEFORE | DAY 1 AFTER TREATMENT 1 | BEFORE TREATMENT 2

Individual patient experiences. Swelling reactions may vary. 87% of adults receiving KYBELLA® in the clinical trials experienced swelling as an adverse reaction.

VISUALIZE PROGRESSIVE RESULTS

Use the sloped chin line to record your patients' improvement throughout their treatment series

BEFORE | 1 TREATMENT | 2 TREATMENTS | 3 TREATMENTS | 4 TREATMENTS

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

Please see additional Important Safety Information on following page.

kybella®

(deoxycholic acid) injection 10 mg/mL

Patient Treatment Plan

Record their journey

Individually tailored* for (patient name)

Patient email

Patient phone number

Total recommended treatments

Treatment **1** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

Treatment **2** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

Treatment **3** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

Treatment **4** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

Treatment **5** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

Treatment **6** Date:	Vial lot number(s):	Expiration date:	Total dose administered (mL):
Notes:			

*Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart.[1]

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see accompanying KYBELLA® full Prescribing Information.

Reference: 1. KYBELLA® Prescribing Information, May 2020.

Allergan Aesthetics
an AbbVie company

hcp.MyKybella.com KYB130463-v2 07/20 007333

kybella®
(deoxycholic acid) injection 10 mg/mL